Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment

Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment

The human papillomavirus (HPV) 9-valent, recombinant vaccine (Gardasil™9) helps protect young adults (males and females) against anogenital cancers and genital warts caused by certain HPV genotypes (ref. Gardasil™9 insert). This vaccine is administered intramuscularly (IM). The aim of this study was...

Full description

Bibliographic Details
Main Authors: Brian K. Meyer, Mark A.F. Kendall, Donna M. Williams, Andrew J. Bett, Sheri Dubey, Renee C. Gentzel, Danilo Casimiro, Angus Forster, Holly Corbett, Michael Crichton, S. Ben Baker, Robert K. Evans, Akhilesh Bhambhani
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:Vaccine: X
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136219300312

Internet

http://www.sciencedirect.com/science/article/pii/S2590136219300312

Similar Items